Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 Monotherapy in Advanced Solid Tumors
NCT02610075Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in solid tumor, sponsored by AstraZeneca. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Dec 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02610075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610075.